BTW
CRL icon

Boston Trust Walden’s Charles River Laboratories CRL Stock Holding History

Boston Trust Walden’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.5M Buy
288,917
+3,492
+1% +$622K 0.5% 68
2026
Q1 		$49.2M Sell
285,425
-19,452
-6% -$3.61M 0.4% 91
2025
Q4 		$60.8M Sell
304,877
-2,365
-0.8% -$429K 0.46% 80
2025
Q3 		$48.1M Buy
307,242
+82,051
+36% +$13M 0.35% 115
2025
Q2 		$34.2M Buy
225,191
+19,789
+10% +$2.64M 0.24% 153
2025
Q1 		$30.9M Buy
205,402
+919
+0.4% +$154K 0.23% 158
2024
Q4 		$37.7M Buy
204,483
+8,338
+4% +$1.61M 0.26% 146
2024
Q3 		$38.6M Sell
196,145
-4,169
-2% -$866K 0.27% 146
2024
Q2 		$41.4M Buy
200,314
+5,375
+3% +$1.22M 0.31% 130
2024
Q1 		$52.8M Sell
194,939
-2,420
-1% -$578K 0.38% 108
2023
Q4 		$46.7M Buy
197,359
+6,462
+3% +$1.27M 0.35% 107
2023
Q3 		$37.4M Buy
190,897
+869
+0.5% +$178K 0.31% 112
2023
Q2 		$40M Buy
190,028
+15,746
+9% +$3.13M 0.33% 113
2023
Q1 		$35.2M Buy
174,282
+33,693
+24% +$7.64M 0.3% 124
2022
Q4 		$30.6M Buy
140,589
+40,316
+40% +$8.8M 0.27% 134
2022
Q3 		$19.7M Sell
100,273
-840
-0.8% -$181K 0.2% 165
2022
Q2 		$21.6M Buy
101,113
+2,211
+2% +$540K 0.2% 160
2022
Q1 		$28.1M Buy
98,902
+14,431
+17% +$4.45M 0.23% 150
2021
Q4 		$31.8M Buy
84,471
+849
+1% +$330K 0.26% 136
2021
Q3 		$34.5M Sell
83,622
-2,059
-2% -$855K 0.31% 119
2021
Q2 		$31.7M Buy
85,681
+9,899
+13% +$3.31M 0.28% 127
2021
Q1 		$22M Buy
75,782
+10,839
+17% +$3.01M 0.21% 155
2020
Q4 		$16.2M Buy
64,943
+1,804
+3% +$430K 0.17% 172
2020
Q3 		$14.3M Buy
63,139
+989
+2% +$205K 0.18% 166
2020
Q2 		$10.8M Sell
62,150
-42,207
-40% -$6.74M 0.15% 191
2020
Q1 		$13.2M Sell
104,357
-42,185
-29% -$6.33M 0.21% 147
2019
Q4 		$22.4M Buy
146,542
+1,791
+1% +$248K 0.26% 121
2019
Q3 		$19.2M Buy
144,751
+1,491
+1% +$200K 0.24% 130
2019
Q2 		$20.3M Sell
143,260
-1,480
-1% -$201K 0.26% 115
2019
Q1 		$21M Buy
144,740
+2,563
+2% +$337K 0.29% 108
2018
Q4 		$16.1M Sell
142,177
-7,136
-5% -$893K 0.26% 111
2018
Q3 		$20.1M Sell
149,313
-5,814
-4% -$718K 0.28% 110
2018
Q2 		$17.4M Buy
155,127
+41,134
+36% +$4.45M 0.26% 123
2018
Q1 		$12.2M Sell
113,993
-8,543
-7% -$921K 0.18% 157
2017
Q4 		$13.4M Buy
+122,536
New +$13.3M 0.2% 150

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
LKIM
Lawson Kroeker Investment Management Omaha, Nebraska $361M AUM 22.26% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Boston Trust Walden's CRL Position: Q2 2026 in Review

Boston Trust Walden increased its Charles River Laboratories (CRL) stake by 1.2% in Q2 2026, buying an estimated $622K and bringing the position to 288,917 shares worth $65.5M. The position accounts for 0.5% of the portfolio, ranked #68.

Boston Trust Walden first reported a position in CRL in Q4 2017 and has held it in 35 quarters since. 156 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Boston Trust Walden held 288,917 shares of Charles River Laboratories worth $65.5M as of Q2 2026.
  • Boston Trust Walden bought 3,492 Charles River Laboratories shares in Q2 2026, an estimated $622K.
  • Charles River Laboratories made up 0.5% of Boston Trust Walden's portfolio in Q2 2026, its #68 holding.
  • Boston Trust Walden first reported a position in Charles River Laboratories in Q4 2017 and has held it in 35 quarters since.
  • 156 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Boston Trust Walden's 13F filing for Q2 2026, filed 24 Jul 2026.